Loading...
Downregulation of GPSM2 is associated with primary resistance to paclitaxel in breast cancer
Paclitaxel is one of the most effective chemotherapy drugs for breast cancer worldwide but 20–30% patients show primary resistance to the drug. Screening and identification of markers that facilitate effective and rapid prediction of sensitivity to paclitaxel is therefore an urgent medical requireme...
Na minha lista:
| Udgivet i: | Oncol Rep |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
D.A. Spandidos
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7041173/ https://ncbi.nlm.nih.gov/pubmed/32020211 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2020.7471 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|